Efficacy News and Research

RSS

$Pivotal Study Supports Use of IMNOVID®▼ Pomalidomide in Patients with Relapsed or Refractory Multiple Myeloma$

Pivotal Study Supports Use of IMNOVID®▼ Pomalidomide in Patients with Relapsed or Refractory Multiple Myeloma

The Lancet Oncology published this week findings from a study, which showed that the new oral therapy IMNOVID®▼ (pomalidomide), used in combination with low-dose dexamethasone demonstrated a significant survival advantage over high-dose dexamethasone alone, in patients with relapsed and refractory multiple myeloma (rrMM).1

5 Sep 2013

Experimental agent fails to increase HDL levels, reveals new study

The search continues for an agent that increases high-density lipoprotein (HDL) and reduces arterial plaque, after the experimental apolipoprotein A1 (apoA1) inducer, RVX-208 failed to do so in the ApoA1 Synthesis Stimulation and Intravascular Ultrasound for Coronary Atheroma Regression Evaluation (ASSURE) study.

5 Sep 2013

Hokusai-VTE findings provide fresh insight into patients with pulmonary embolism

In the treatment of venous thromboembolism (VTE), the oral anticoagulant edoxaban resulted in equal efficacy and better safety compared to standard warfarin when either drug was used with initial low molecular weight heparin (LMWH), according to the results of the Hokusai-VTE trial.

5 Sep 2013

Rigel plans to focus on completing three clinical programs for ITP, DLE and dry eye disease

Rigel Pharmaceuticals, Inc. today announced its plans to focus the Company's resources on the completion of three lead clinical programs. These efforts include commencing a Phase 3 clinical study of fostamatinib, an oral SYK inhibitor, in Immune Thrombocytopenic Purpura pending discussions with regulatory agencies.

5 Sep 2013

Neurodyn acquires all assets related to new drug candidate Memogain from Galantos Pharma

Neurodyn Inc. announced today that it has acquired from Galantos Pharma GmbH, Mainz, Germany all assets related to their Alzheimer's prescription drug candidate - Memogain. Memogain has completed an extensive preclinical development program and is ready to proceed into Phase 1 clinical trials in late 2013. The terms of the acquisition were not disclosed.

5 Sep 2013

Affinium initiates dosing in Phase 1 IV clinical trial of antibiotic prodrug, AFN-1720

Affinium Pharmaceuticals announced today that it has initiated dosing in a Phase 1 intravenous clinical trial of its new antibiotic prodrug, AFN-1720. AFN-1720 is the prodrug of the active drug, AFN-1252.

5 Sep 2013

Increased mortality in schizophrenia ‘not attributable to drug therapy’

The increased mortality risk observed among patients with severe psychiatric illness, including schizophrenia, does not seem to be attributable to use of psychopharmacologic therapy, study findings indicate.

4 Sep 2013

Endo, BDSI complete interim analyses of Phase III trials for BEMA Buprenorphine

Endo Pharmaceuticals Inc., a subsidiary of Endo Health Solutions Inc., and BioDelivery Sciences International, Inc. announced today that the companies have completed interim analyses of both the opioid naive and opioid experienced Phase III trials for BEMA Buprenorphine.

4 Sep 2013

Radiologists train military physicians to remove foreign bodies with ultrasound-guided techniques

William E. Shiels II, DO, chief of the Nationwide Children's Hospital Department of Radiology and president of Children's Radiological Institute, Inc., is leading a team of radiologists for the training of military physicians to remove shrapnel foreign bodies from warfighters with ultrasound-guided techniques that he originally developed, with subsequent improvements made by the full team of Nationwide Children's Hospital interventional radiologists.

4 Sep 2013

RVX-208 drug fails to increase good cholesterol levels in ASSURE trial

Patients with coronary artery disease and low levels of "good cholesterol - or high-density lipoprotein - who were treated with a drug designed to increase HDL levels and reduce coronary plaque build-up, experienced no better results than those treated with placebo, according to research conducted by the Cleveland Clinic Coordinating Center for Clinical Research.

4 Sep 2013

Aliskiren does not slow progression of coronary atherosclerosis in prehypertension patients

Among patients with prehypertension and coronary artery disease, use of the renin (an enzyme secreted by the kidneys) inhibitor aliskiren, compared with placebo, did not result in improvement or slowing in the progression of coronary atherosclerosis, according to a study published by JAMA. The study is being released early online to coincide with its presentation at the European Society of Cardiology Congress 2013.

4 Sep 2013

Esperion Therapeutics reports positive results from ETC-1002 Phase 2a study for LDL-C treatment

Esperion Therapeutics, Inc., a clinical-stage biopharmaceutical company, today announced positive top-line results from a Phase 2a study of ETC-1002 when added to statin therapy in patients with elevated levels of low density lipoprotein cholesterol (LDL-C or "bad cholesterol").

4 Sep 2013

Apitope successfully completes ATX-MS-1467 Phase I trial in relapsing MS patients with positive results

Apitope, the drug discovery and development company focused on treating the underlying cause of autoimmune diseases, today announced completion with positive results of its second Phase I clinical trial of ATX-MS-1467.

3 Sep 2013

Imaxio's pro-immunogenic technology used in tuberculosis vaccine phase I clinical study

Imaxio, a biopharmaceutical company specializing in vaccines and genomics, announces today that IMX313, its proprietary pro-immunogenic technology, has been administered for the first time in humans in a tuberculosis vaccine phase I clinical study. The trial is being conducted by the Jenner Institute at Oxford University, England.

3 Sep 2013

Renin inhibitor aliskiren not effective in slowing progression of coronary atherosclerosis

3 Sep 2013

Omecamtiv mecarbil fails to achieve primary endpoint in phase II ATOMIC-AHF study

Omecamtiv mecarbil, a cardiac myosin-activator, did not achieve its primary efficacy endpoint in reducing dyspnoea (shortness of breath) in patients with acute heart failure, according to the results of the phase II ATOMIC-AHF (Acute Treatment with Omecamtiv Mecarbil to Increase Contractility in Acute Heart Failure) study.

3 Sep 2013

Acacia Pharma raises $23.5 million in Series B financing

Acacia Pharma, a pharmaceutical company specialising in the development of drugs for supportive care, announces it has raised £15 million (~$23.5 million) in a Series B financing led by Fidelity Biosciences and Novo A/S.

3 Sep 2013

Facebook groups are effective tool for increasing HIV testing among at-risk populations

Peer-led Facebook groups are an acceptable and effective tool for increasing home-based HIV testing among at-risk populations. HIV infection is a major health concern for men who have sex with men (MSM), especially among African Americans and Latinos who have high rates of incident cases and new diagnoses.

3 Sep 2013

Argininosuccinic aciduria (ASA) and gene therapy: an interview with Dr Julien Baruteau, UCL Institute for Women's Health, London

This rare genetic condition can theoretically affect patients at any age but symptoms are more often observed in childhood and even uncommonly during the first days of life.

2 Sep 2013

Women are 25% less likely to die post TAVI than men, says doctor

Dr Sherif said: "Earlier studies on the impact of gender on outcome after transcatheter aortic valve implantation (TAVI) have had conflicting results. A Canadian study reported in 641 consecutive patients that female sex is associated with a better long-term and short-term survival after TAVI.1 An Italian study of 305 high risk patients found no gender differences in composite safety and efficacy endpoints at 30 days and one year after TAVI."2

2 Sep 2013

Efficacy News and Research

Pivotal Study Supports Use of IMNOVID®▼ Pomalidomide in Patients with Relapsed or Refractory Multiple Myeloma

Experimental agent fails to increase HDL levels, reveals new study

Hokusai-VTE findings provide fresh insight into patients with pulmonary embolism

Rigel plans to focus on completing three clinical programs for ITP, DLE and dry eye disease

Neurodyn acquires all assets related to new drug candidate Memogain from Galantos Pharma

Affinium initiates dosing in Phase 1 IV clinical trial of antibiotic prodrug, AFN-1720

Increased mortality in schizophrenia ‘not attributable to drug therapy’

Endo, BDSI complete interim analyses of Phase III trials for BEMA Buprenorphine

Radiologists train military physicians to remove foreign bodies with ultrasound-guided techniques

RVX-208 drug fails to increase good cholesterol levels in ASSURE trial

Aliskiren does not slow progression of coronary atherosclerosis in prehypertension patients

Esperion Therapeutics reports positive results from ETC-1002 Phase 2a study for LDL-C treatment

Apitope successfully completes ATX-MS-1467 Phase I trial in relapsing MS patients with positive results

Imaxio's pro-immunogenic technology used in tuberculosis vaccine phase I clinical study

Renin inhibitor aliskiren not effective in slowing progression of coronary atherosclerosis

Omecamtiv mecarbil fails to achieve primary endpoint in phase II ATOMIC-AHF study

Acacia Pharma raises $23.5 million in Series B financing

Facebook groups are effective tool for increasing HIV testing among at-risk populations

Argininosuccinic aciduria (ASA) and gene therapy: an interview with Dr Julien Baruteau, UCL Institute for Women's Health, London

Women are 25% less likely to die post TAVI than men, says doctor

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News